Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04250350 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 3 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT04250350 is a Phase 3 study of Atopic Dermatitis that has completed, run by Eli Lilly and Company. The registered enrollment target is 206 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT04250350, a Phase 3 study of Atopic Dermatitis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to \<18 years weighing ≥40 kilograms) with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.
Conditions Studied
Interventions
- BIOLOGICAL Lebrikizumab
Study Locations (20)
Florida
- C&R Research Services USA - Coral Gables
- Florida Academic Centers Research and Education, LLC - Coral Gables
- Pediatric Skin Research, LLC - Coral Gables
- Encore Medical Research - Hollywood
- Solutions Through Advanced Research, Inc. - Jacksonville
- Well Pharma Medical Research Corp. - Miami
- Sanchez Clinical Research Inc - Miami
- Miami Dermatology and Laser Research - Miami
- Park Avenue Dermatology - Orange Park
- ForCare Clinical Research - Tampa
California
- Hope Clinical Research - Canoga Park
- First OC Dermatology - Fountain Valley
- MD Studies - Fountain Valley
- Integrative Skin Science and Research - Sacramento
- University of California, San Diego/Rady Children's Hospital, San Diego - Pediatric & Adolescent Dermatology - San Diego
- Southern California Dermatology, Inc. - Santa Ana
Alabama
- Pinnacle Research Group - Anniston
Arkansas
- Arkansas Research Trials, LLC - North Little Rock
Colorado
- IMMUNOe International Research Centers - Centennial
Georgia
- Georgia Pollens Clinical Research Centers, Inc - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2020-02-11 |
| Est. Completion | 2022-06-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04250350
The ClinicalTrials.gov registry entry for NCT04250350 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (66% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT04250350 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04250350 about?
NCT04250350 is a clinical study titled "Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis". This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to \<18 years weighing ≥40 kilograms) with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.
What is the current status of trial NCT04250350?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2020-02-11. Estimated completion is 2022-06-22.
What conditions does trial NCT04250350 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT04250350?
The interventions under investigation include: Lebrikizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04250350?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04250350 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.